Crossmark

A novel microfluidic device capable of maintaining functional thyroid carcinoma specimens ex vivo provides a new drug screening platform

Crossref DOI link: https://doi.org/10.1186/s12885-019-5465-z

Published Online: 2019-03-22

Published Print: 2019-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Riley, Andrew

Green, Victoria

Cheah, Ramsah

McKenzie, Gordon

Karsai, Laszlo

England, James

Greenman, John https://orcid.org/0000-0002-6003-6051
Funding

Funding for this research was provided by:

Allam Studentship (N/A)
License Information

Text and Data Mining valid from 2019-03-22
More Information

Article History

Received: 23 October 2018

Accepted: 13 March 2019

First Online: 22 March 2019

Ethics approval and consent to participate

: The project had received ethical approval from North East-Newcastle and North Tyneside Research Ethics Committee (15/NE/0412) and was approved by Hull and East Yorkshire NHS Trust R&D (R1925). Patient tissue samples were taken after obtaining written, informed, consent.

: Not applicable.

: The authors declare that they have no competing interests.

: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.